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Does rotation thrombelastometry (ROTEM) improve 
early prediction of coagulopathy in  breast tumor?
Abstract
Background and purpose: Breast Cancer is the second most common 
cancer among women after skin carcinoma. Incindence in Croatia in 2012 
was 2227 new cases per year with mortality 1033 women per year. One of 
the most pronaunced caracteristics of cancers in general are changes in co-
agulation factors. Except usual coagulation factors there is thrombelasom-
etry which is dynamic method for evaluation of coagulation factors. We have 
been used thrombelastometry to see differences in coagulation factors for 
carcinomas and benign breast diseases.
Materials and Methods: We included 132 patients with benign and 
malignant breast diseases in Institute of Thumors, Clinical Hospital Center 
“Sisters of Mersy”, Zagreb, Croatia gathered in prospective study in 
2012/2013. We compared differences in coagulation parameters with 
throm belastometry and usual coagulation factors in earlier mentioned two 
groups of patients with Mann-Whitney U test what is graficly described with 
Box and Whiskers plots and correlatio coefficients are described in table with 
Spearman correlation coefficients.
Results: A5,A10,A15,A20,A25 and A30, MCF and AUC intem are 
significatly higher in malignant breast disease patients. Significant trend of 
elevation of these values is present in both patients groups, but those are si-
gificantly higher in patient group with malignant tumors. While in patients 
group with malignant tumors almost every correlation coefficients between 
A5-A30, MCF and AUC intem and cogulation markers are significant, 
those correlations among patients with benign diseases are not significant. 
Those values suggests that A5-A30, MCF and AUC intem are significatly 
correlated with most common used coagulation markers only in patients 
with malignant diseases.
Conclusions: There are differences in coagulation factors in patients 
with benign and malignant breast diseases. Trend of elevation of markers 
of coagulation values is present in both disease, but significantly higher 
values are in malignant tumor. Our results are based on small numbers and 
larger number of patients with precise data of coagulation parameters are 
still needed.
IntroductIon
Breast cancer is the second most common cancer afer skin cancers and it is first cause of death from malignant tumors in women. The 
most common type of breast is ductal carcinoma (NST) which begins 
in the linining of the milk ducts. Another type of breast cancer is lobu-
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CFT = k – clot formation time  
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breast cancer is breast cancer that has spread from where 
it began in the breast ducts or lobules to surrounding 
normal tissue. The incidence in Croatia is around 2300 
new cases of breast carcinoma in women with around 800 
deaths  from these disease in 2013. in University Hospital 
for Tumors 600 patients had breast biopsy for suspitious 
breast tumors and afterward therapy after protocol for 
breast cancer. Surgical treatment have been based on bi-
opsy for suspicious breast tumors and emergency patohis-
tological analysis. Patients with carcinomas are at risk of 
coagulopathy which can be the first sign of malignant 
disease.
The hemostatic system with its procoagulant effects 
mediated directly by cancer cells are considered to play 
principal role in the development of cancer-induced hy-
percoagulability and major thromboembolic complica-
tions (1). 
Recently, rotation thrombelastometry (ROTEM)  is a 
method to evaluate the whole process of blood coagula-
tion as a graph from the beginning of clot formation to 
fibrinolysis providing information related to the cumula-
tive effects of various parameters of all stages of the co-
agulation and fibrinolytic processes (2).
The  benefits of ROTEM_ technology include rapid 
availability of test results and enhanced reproducibility 
the data  which are also continuous, digital, and retriev-
able for further calculations (3, 4).
The goal of the study is to prove connection between 
changes in coagulation factors and pathystological analy-
sis. In the study standard methods for coagulation factors 
analysis and thrombelastometry (ROTEM) have been 
used. Thrombelastometry gives quantitive and graphic 
measurment from inicial thromb formation to its retrac-
tion and lysis. Coagulation factors  in correlation with 
patohistological analysis will contribute to better under-
standing perioperative treatment of benign changes and 
malignat breast tumors and more rational thrombopro-
filaxis and treatment with anticoagulant and antiagrega-
tion therapy. 
MAterIAls And Methods
Using information after prospective study2012/2013. 
in University Hospital for Tumors, University Hospital 
Center “Sisters of Mersy”, Zagreb, Croatia. Our study 
have been included 132 patients:59 of those had a breast 
cancer and all the rest(73) benign breast disease. All pa-
tients had mean age 59,15 +- 11,6.  This study have been 
done with aproval of Etical Commity of School of Medi-
cine, University of Zagreb and University Hospital Cen-
ter “Sisters of Mersy” in Zagreb.All hospitals, pathology 
laboatories and coagulation parameters laboratories where 
from University Hospital Center “Sisters of Mersy”. Pa-
tohistological samples where surgicaly removed by traind 
specialists for oncologic breast surgery. Patohistological 
analysis were analysed by trained patologists who are spe-
cialised for breast surgery tumors. Mean tumor size were 
20,0 +- 11,2 mm.  Breast cancer staging was based on 
pathologic tumor-node-metastasis (TNM) classification. 
We also analysed therapy after surgery (Chemotherapy, 
radiotherapy or unknown). 
From coagulation factors we analysed FVIII, PC, PT, 
INR  PT. We also used rotation thromelastometry 
(ROTEM) in all patients and analysed A5, A10, A15, 
A20, A25, A30 intem, MCF intem and AUC intem. We 
analysed with differences in this coagulation factors 
among patients benign and malignant breast diseases.
Patients with preexisting hematological or coagulation 
disorders, those taking anticoagulants and those with 
liver or renal dysfunction were excluded from the study. 
Sample collection for subsequent coagulation analysis 
blood samples were drawn into 4.5 ml vacutainers (Bec-
ton Dickinson) containing 3.2% trisodium citrate with a 
citrate/ blood ratio of 1:9.  and for platelet count into 
Becton Dickinson EDTA tubes.
coagulation analyses
The  laboratory tests of coagulation were performed on 
full automated STA compact device of Diagnostica ST-
AGO for all patients: platelet count, prothrombin time 
(PT) and activated partial thromboplastin time (APTT), 
fibrinogen, and D-Dimer. The normal ranges for these 
tests are: APTT (26–36 s), PT (9.4–15.4 s), Fibrinogen 
(200– 400 mg/dl), and D-Dimer (0.00–0.50 lg/ml).
roteM_ thrombelastographic analysis
Thrombelastography analysis was performed with the 
ROTEM_ Coagulation Analyzer (Pentapharm, Munich, 
Germany). Four channels were available for simultaneous 
measurements. Each test required 300 ll citrated whole 
blood. The blood was re-calcified with 20 nl 0.2 mol/l 
CaCl2 (star-TEM_; Pentapharm, Munich, Germany) 
and activation of coagulation was performed with differ-
ent agents:
INTEM: Contact pathway activation of the coagula-
tion with 20 nl of contact activator (partial thromboplas-
tin–phospholipid from rabbit brain extract and ellagic 
acid, in-TEM_; Pentapharm, Munich, Germany).
EXTEM: Tissue factor pathway activation of the co-
agulation with 20 nl of tissue factor (TF, tissue thrombo-
plastin from rabbit brain extract, ex-TEM_; Pentapharm, 
Munich,Germany).
APTEM: TF plus 20 nl of aprotinin, plasmin-antag-
onist (ap-TEM_; Pentapharm, Munich, Germany).
FIBTEM: TF plus inhibition of thrombocytes with 
20 nl of cytochalasin (fib-TEM_; Pentapharm, Munich, 
Germany).
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The test starts automatically after injection of the 
blood sample with an automated pipette and calculated 
graphical results are obtained by the integrated computer 
of the device. All ROTEM samples were analyzed within 
30–90 min of blood collection.
The following ROTEM_ parameters were determined: 
clotting time (CT = R) represents a measure of the initia-
tion of clot formation, clot formation time (CFT = k) 
represents the speed of clot formation, and maximum clot 
formation (MCF = MA) represents maximum clot 
strength.
statistics
Data were shown in tables in figure. Descriptive stas-
tics were made to describe investigated patients sample 
Kolmogorov-Smirnov test was used to analyse data nor-
mality and due to its results appropriate non-parametric 
tests were used in following analysis. Differences between 
patients with malignant and benign breast disease were 
analysed with Mann-Whitney U test. Correlations be-
tween A5-A30, MCF and AUC intem and coagulation 
markers regarding malignant and benign breast disease 
were done with Spearman correlations coefficients. All P 
values below 0,05 were consindered significant. IBM 
SPSS Stastistics version 19.0.01. had been used as stastis-
tical software (www.spss.com).
results
Majority of patients: 35 (59,3%) had tumor grade 2, 
39 (66,1%) had LumTP grade B. Among those patients 
that have valid data  from TNM clasification (N=28) 13 
(46,4%) had T grade 2, 18 (64,3%) N grade 0 and 13 
(46,4%) M grade 1 (metastasis in lymphatic nodules). 
Average tumor size was 20,0 +- 11,2 mm. There was no 
significan age difference between benign and malignant 
breast disease group (Z = -0,5; p=0,540; Mann-Whitney 
U test)
A5, A10,A15,A20, A25, A30, MCF and AUC intem 
values are significantly higher in malignant breast disease. 
Table 2. shows descriptive statistics and differences be-
tween benign and malignant breast disease regarding A5-
A30, MCF, AUC intem and coagulation markers. Sig-
nificant trend of elevation these values is present in both 
TAblE 1































Without data 31 52,5%
Therapy
Without data 15 25,4%
Chemotherapy 11 18,6%
Radiotherapy 33 55,9%
Age (years):  
mean ± SD 59,15 ± 11,6
Tumor size (mm): 
mean ± SD 20,0 ± 11,2
Figure 1. Differences in A5 – A30 intem values in benign and 
malign breast disease.
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group (p;0,001; Friedeman test), but significantly higher 
values in group with malignant tumor (Figure 1). 
While in patients with malignant disease almost every 
correlation coefficients between A5 –A30, MCF and 
AUC intem coagulation markers are significant,those cor-
relations among patients with benign disease are not sig-
nificant. Among patients with malignant disease positive 
correlations were found between A15-A30,MCF and 
AUC intem and FVIII and PC. Significant negative cor-
relations were found with PV and INRPV. Different pat-
terns of significant correlations between A5-A30, MCF 
and AUC intem and coagulation markers regarding ma-
lignant and benign breast disease are shown in Table 3.
dIscussIon
Although breast cancer is one of the most common 
carcinoma in women there are small number of studies 
which analyse differences between malignant and benign 
breast disease with rotation thrombelastometry  and cor-
relations between thrombelastometry factors and coagu-
lation factors which we used in our study. 
After analyzing all gethered data from our prospective 
study we concluded that there are strong connection be-
tween A5, A10, A15, A20, A25 i A30, MCF and AUC 
intem with malignant disease and that it is significantly 
higher in group with malignant diseases than in group 
with benign breast diseases. Also our values suggests that 
A5-A30, MCF and AUC intem are significantly corre-
lated with most common used coagulation markers only 
in patients with malignant disease. 
The strength of our study is that we find differencies 
in specific  coagulation parameters with thrombelastom-
etry and standard coagulation tests in patients with ma-
lignant disease and we proved significant difference in 
some specific parameters what we mentioned earlier. 
Many studies demonstrates thromboelastographic 
evidence of hypercoagulability in patients suffering from 
cancer  with a high rate of venous thromboembolic events 
(5).Thrombotic episodes may also precede the diagnosis 
of cancer by months or years thus representing a potential 
marker for occult malignancy (6). Abnormal hemostasis 
has been reported in cancer patients, including the short-
ening of the activated partial thromboplastin time, ele-
vated levels of coagulation proteins (fibrinogen, factors V, 
VIII, IX, and XI), thrombocytosis, elevated fibrin/fibrin-
ogen degradation products, and an accelerated rate of fi-
brinogen turnover (5). 
Hypercoagulability is difficult to detect by standard 
coagulation tests in cancer patients, but ROTEM (7), is 
TAblE 2
Differences in significant correlations between A5-A30, MCF and AUC intem and coagulation mark-
ers regarding malignant and benign breast disease: Spearman correlation.
   
Malignant disease Benign disease
N=59 N=70
  FVIII PC PVs INRPV FVIII PC PVs INRPV
A5 intem
Rho 0,251 0,149 –0,290 –0,261 –0,005 0,081 –0,040 –0,057
P 0,055 0,259 0,026 0,046 0,967 0,505 0,741 0,637
A10 intem
Rho 0,256 0,235 –0,334 –0,313 0,072 0,093 –0,075 –0,093
P 0,050 0,073 0,010 0,016 0,553 0,442 0,537 0,445
A15 intem
Rho 0,298 0,267 –0,332 –0,314 0,100 0,108 –0,090 –0,111
P 0,022 0,041 0,010 0,016 0,412 0,373 0,458 0,361
A20 intem
Rho 0,289 0,287 –0,334 –0,304 0,146 0,139 –0,135 –0,144
P 0,026 0,028 0,010 0,019 0,227 0,251 0,266 0,234
A25 intem
Rho 0,316 0,293 –0,330 –0,297 0,200 0,148 –0,145 –0,158
P 0,015 0,024 0,011 0,022 0,098 0,221 0,232 0,191
A30 intem
Rho 0,314 0,280 –0,310 –0,270 0,222 0,169 –0,168 –0,185
P 0,016 0,032 0,017 0,039 0,064 0,161 0,165 0,125
MCF 
intem
Rho 0,284 0,279 –0,326 –0,298 0,180 0,127 –0,128 –0,136
P 0,029 0,033 0,012 0,022 0,135 0,294 0,289 0,260
AUC 
intem
Rho 0,311 0,297 –0,326 –0,289 0,219 0,135 –0,117 –0,112
P 0,016 0,022 0,012 0,027 0,069 0,264 0,336 0,358
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a sensitive method that is able to identify and measure 
hypercoagulability, which is not detected by routine lab-
oratory tests (8, 9, 7). ROTEM, by using whole blood, 
measures both quantity of clotting and, most important-
ly quality of clotting which is not recorded by routine 
coagulation profile (10.4). Hypercoagulability was diag-
nosed readily by the presence of an accelerated clot forma-
tion, as evidenced by shortening of CFT and an increase 
of the clot strength, as evidenced by increasing of MCF. 
ROTEM_ tracings on all assays (INTEM, EXTEM, 
FIBTEM, APTEM) revealed a statistically significant 
increasing of MCF in cancer patients. While it is likely 
that certain cancer types are more prone to thrombosis 
(11), we could not predict which tumors are most com-
monly associated with thrombosis since ROTEM param-
eters did not differ among cancer subgroups. 
In the literature, postoperative hypercoagulability, de-
tected by TEG, has been reported in patients undergoing 
hepatic surgery (12), general abdominal procedures (13, 
14), and neurosurgery (15). Other clinical settings associ-
ated with hypercoagulability detected by TEG include 
ischemic heart disease (16), end-stage renal failure (17), 
insertion of cutdown intravenous catheters (18) exposure 
to oral contraceptives (19). 
Thromboelastographic analysis of hypercoagulability 
has been also performed in patients with malignancies in 
the earlier literature using first the native whole blood 
TEG and then the celite-activated TEG (21, 22). Our 
findings are by utilizing a newer and more powerful tech-
nique, the modified rotation thromboelastogram ana-
lyzer, ROTEM_. Hyperfibrinogenemia and thrombocy-
tosis have been frequently reported in patients with 
malignant disorders (23, 24). We therefore sought to cor-
relate these laboratory parameters with those of ROTEM_ 
and observed that MCF had a strong positive correlation 
with plasma fibrinogen concentration and platelet counts. 
MCF measures the maximum clot strength, which is de-
pendent on platelet function and fibrinogen level. The 
contribution of platelet component and fibrinogen to the 
clot strenght has been demonstrated in adult patients 
without tumors (25, 26, 27, 28). 
Since ROTEM demonstrates hemostasis as a whole 
dynamic process, ROTEM data gives more information 
on interaction between platelets and the coagulation cas-
cade rather than the conventional coagulation screens; 
PT, APTT, platelet count, and fibrinogen concentrations. 
Identification by the ROTEM of a hypercoagulable state 
in  patients  with breast tumor may help to identify those 
at risk for cancer-induced thromboembolic events and the 
test may be more valuable if combined with scoring sys-
tems for grading deep vein leg thrombosis (29). Further 
investigations that correlate this hypercoagulability with 
the clinical picture are needed to determine if TEG data 
can be applied on therapeutic interventions in this patient 
population.
On the other hand, the limitation of this study are the 
small number of patients and we recomend to make a 
larger study with patients with malignant breast diseases 
which will confirm our data and which will help in future 
to diagnose breast tumors before even we found them 
with other diagnostic  means. The thing is that coagula-
tion disorders can be one of the first signs of malignant 
disease and that this can help us to discover the disease 
in the earlier stage and to make better prognosis in the 
end.
conclusIon
In patients with malignant breast disease almost every 
correlation ROTEM coefficients between A5 –A30, MCF 
and AUC intem coagulation markers are significant,but 
those correlations among patients with benign disease are 
not significant. Among patients with malignant disease 
positive correlations were found between A15-A30, MCF 
and AUC intem and FVIII and PC and significant nega-
tive correlations were found with PV and INR. Signifi-
cant trend of elevation hypercoagulability values is pres-
ent in both disease but significantly higher values in 
malignant breast tumor. Rotation thrombelastometry 
(ROTEM) may improve early prediction of coagulopathy 
in (benign and malign)  breast tumor?
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